Cost-efficiency and budget-neutral expanded access modeling of the novel PD-1 inhibitor toripalimab versus pembrolizumab in recurrent or metastatic nasopharyngeal carcinoma.
Sign Up to like & getrecommendations! Published in 2024 at "Journal of medical economics"
DOI: 10.1080/13696998.2024.2331905
Abstract: Aims: To estimate, in the setting of recurrent or metastatic nasopharyngeal carcinoma (R/M NPC) for an assumed 1,207 incident US cases in 2024, (1) the cost-efficiency of a toripalimab-gemcitabine-cisplatin regimen compared to a similar pembrolizumab… read more here.
Keywords: cost; rate; budget neutral; expanded access ... See more keywords
Are Budget Neutral Income Floors Fiscally Viable in Sub-Saharan Africa?
Sign Up to like & getrecommendations! Published in 2023 at "Journal of African Economies"
DOI: 10.1093/jae/ejac049
Abstract: We use microsimulations to assess whether budget-neutral universal income floors are fiscally viable in twelve Sub-Saharan African countries. We consider three universal basic income scenarios of decreasing levels of generosity: poverty line, average poverty gap… read more here.
Keywords: budget neutral; floors fiscally; budget; income floors ... See more keywords